<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34720198</PMID><DateRevised><Year>2022</Year><Month>02</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0026-9298</ISSN><JournalIssue CitedMedium="Print"><Volume>169</Volume><Issue>11</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde</Title><ISOAbbreviation>Monatsschr Kinderheilkd</ISOAbbreviation></Journal><ArticleTitle>[Coronavirus disease 2019 in childhood and adolescence].</ArticleTitle><Pagination><StartPage>1010</StartPage><EndPage>1033</EndPage><MedlinePgn>1010-1033</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00112-021-01326-2</ELocationID><Abstract><AbstractText>The coronavirus disease 2019 (COVID&#x2011;19) mostly occurs in children and adolescents as an asymptomatic infection. The course of the disease is usually mild or moderate. The estimated seroprevalence in Germany before the start of the vaccination program in children and adolescents was &gt;&#x202f;10%. Individual risk factors for a&#xa0;severe course are known. The COVID&#x2011;19-associated pediatric inflammatory multisystem syndrome (PIMS) is a&#xa0;very rare and severe disease with a&#xa0;favorable prognosis if diagnosed early and treated appropriately. The data situation on long-COVID syndrome in children and adolescents is still insufficiently defined and the incidence is not known. The primary source of infections in children and adolescents are household contacts. Transmission in school settings and other day care facilities play a&#xa0;subordinate role, at least in Germany.Two mRNA vaccines are currently approved in Europe for the prevention of COVID&#x2011;19 in children and adolescents above the age of 12&#xa0;years. Except for the very rare occurrence of pericarditis/myocarditis in temporal association with the vaccination, especially in young men, the COVID&#x2011;19 vaccines are considered effective and safe in the age group&#xa0;12-17&#xa0;years. The Standing Vaccination Commission (STIKO) issued a&#xa0;vaccination recommendation for all 12-17-year-olds on 19 August 2021.</AbstractText><CopyrightInformation>&#xa9; Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zepp</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Zentrum f&#xfc;r Kinder- und Jugendmedizin, Universit&#xe4;tsmedizin, Johannes-Gutenberg-Universit&#xe4;t, Langenbeckstr.&#xa0;1, 55131 Mainz, Deutschland.</Affiliation><Identifier Source="GRID">grid.5802.f</Identifier><Identifier Source="ISNI">0000 0001 1941 7111</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knuf</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>P&#xe4;diatrische Infektiologie, Klinik f&#xfc;r Kinder und Jugendmedizin, Klinikum Worms, Universit&#xe4;tsmedizin Mainz, Mainz, Deutschland.</Affiliation><Identifier Source="GRID">grid.5802.f</Identifier><Identifier Source="ISNI">0000 0001 1941 7111</Identifier></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>&#x201e;Coronavirus disease 2019 (COVID&#x2011;19)&#x201c; im Kindes- und Jugendalter: Klinik, Epidemiologie und Impfprogramme.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Monatsschr Kinderheilkd</MedlineTA><NlmUniqueID>8206462</NlmUniqueID><ISSNLinking>0026-9298</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Monatsschr Kinderheilkd. 2022;170(2):167-168. doi: 10.1007/s00112-022-01416-9</RefSource><PMID Version="1">35095116</PMID></CommentsCorrections></CommentsCorrectionsList><OtherAbstract Type="Publisher" Language="ger"><AbstractText>Bei Kindern und Jugendlichen nimmt die &#x201e;coronavirus disease 2019&#x201c; (COVID&#x2011;19) meist einen milden Verlauf. Der Anteil asymptomatischer Infektionen ist hoch. Die gesch&#xe4;tzte Seropr&#xe4;valenz betrug in Deutschland vor Beginn der Impfungen in dieser Altersgruppe &gt;&#x202f;10&#x202f;%. Es sind einzelne Risikofaktoren f&#xfc;r einen schweren Verlauf bekannt. Das COVID&#x2011;19-assoziierte &#x201e;pediatric inflammatory multisystem syndrome&#x201c; (PIMS) ist eine sehr seltene, schwere Erkrankung, die bei fr&#xfc;her Diagnose und ad&#xe4;quater Therapie eine g&#xfc;nstige Prognose hat. Die Datenlage zu Long-COVID in dieser Altersgruppe ist noch unzureichend. Die prim&#xe4;re Quelle von Infektionen bei Kindern und Jugendlichen sind Haushaltskontakte. &#xdc;bertragungen in Schulen und anderen Betreuungseinrichtungen spielen eine untergeordnete Rolle. Zur Pr&#xe4;vention von COVID&#x2011;19 bei Kindern und Jugendlichen sind derzeit in Europa 2&#xa0;mRNA-Impfstoffe ab dem Alter von 12&#xa0;Jahren zugelassenen. Bis auf das sehr seltene Auftreten von Peri&#x2011;/Myokarditiden in zeitlichem Zusammenhang mit der Impfung, insbesondere bei jungen M&#xe4;nnern, sind die COVID&#x2011;19-Impfstoffe in der Altersgruppe&#xa0;12 bis 17&#xa0;Jahre wirksam und sicher. Die St&#xe4;ndige Impfkommission (STIKO) hat am 19.08.2021 eine Impfempfehlung f&#xfc;r alle 12- bis 17-J&#xe4;hrigen ausgesprochen.</AbstractText><CopyrightInformation>&#xa9; Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2021.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19-Vaccination</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">Myocarditis</Keyword><Keyword MajorTopicYN="N">Pediatric multisystem inflammatory disease, COVID&#x2011;19 related</Keyword><Keyword MajorTopicYN="N">SARS-CoV&#x2011;2 infection</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>1</Day><Hour>8</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34720198</ArticleId><ArticleId IdType="pmc">PMC8543413</ArticleId><ArticleId IdType="doi">10.1007/s00112-021-01326-2</ArticleId><ArticleId IdType="pii">1326</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vygen-Bonnet S, Koch J, Armann J, Berner R, Bogdan C, Harder T, et al. Beschluss der STIKO zur 9.&#xa0;Aktualisierung der COVID&#x2011;19-Impfempfehlung und die dazugeh&#xf6;rige wissenschaftliche Begr&#xfc;ndung. Epidemiol Bull. 2021;33:3&#x2013;46. doi: 10.25646/8942.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.25646/8942.2</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol. 2020;92:401&#x2013;402. doi: 10.1002/jmv.25678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25678</ArticleId><ArticleId IdType="pmc">PMC7166628</ArticleId><ArticleId IdType="pubmed">31950516</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui DS, Azhar EI, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health&#x2014;the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264&#x2013;266. doi: 10.1016/j.ijid.2020.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.01.009</ArticleId><ArticleId IdType="pmc">PMC7128332</ArticleId><ArticleId IdType="pubmed">31953166</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO (2020) WHO director-general&#x2019;s opening remarks at the media briefing on COVID&#x2011;19. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020. Zugegriffen: 20. M&#xe4;rz 2020</Citation></Reference><Reference><Citation>Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727&#x2013;733. doi: 10.1056/NEJMoa2001017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708&#x2013;1720. doi: 10.1056/NEJMoa2002032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV&#x2011;2 infection and the potential for reinfection. J Gen Virol. 2020;101:791&#x2013;797. doi: 10.1099/jgv.0.001439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.001439</ArticleId><ArticleId IdType="pmc">PMC7641391</ArticleId><ArticleId IdType="pubmed">32430094</ArticleId></ArticleIdList></Reference><Reference><Citation>Liguoro I, Pilotto C, Bonanni M, Ferrari ME, Pusiol A, Nocerino A, et al. SARS-COV-2 infection in children and newborns: a&#xa0;systematic review. Eur J Pediatr. 2020;179:1029&#x2013;1046. doi: 10.1007/s00431-020-03684-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-020-03684-7</ArticleId><ArticleId IdType="pmc">PMC7234446</ArticleId><ArticleId IdType="pubmed">32424745</ArticleId></ArticleIdList></Reference><Reference><Citation>Viner RM, Ward JL, Hudson LD, Ashe M, Patel SV, Hargreaves D, et al. Systematic review of reviews of symptoms and signs of COVID&#x2011;19 in children and adolescents. Arch Dis Child. 2020 doi: 10.1136/archdischild-2020-320972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/archdischild-2020-320972</ArticleId><ArticleId IdType="pubmed">33334728</ArticleId></ArticleIdList></Reference><Reference><Citation>Molteni E, Sudre C, Canas L, Bhopal S, Hughes R, Antonelli M, et al. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV&#x2011;2. Lancet Child Adolesc Health. 2021 doi: 10.1016/S2352-4642(21)00198-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(21)00198-X</ArticleId><ArticleId IdType="pmc">PMC8443448</ArticleId><ArticleId IdType="pubmed">34358472</ArticleId></ArticleIdList></Reference><Reference><Citation>Abi Nassif T, Fakhri G, Younis NK, Zareef R, Al Amin F, Bitar F, et al. Cardiac manifestations in COVID&#x2011;19 patients: a focus on the pediatric population. Can J Infect Dis Med Microbiol. 2021 doi: 10.1155/2021/5518979.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/5518979</ArticleId><ArticleId IdType="pmc">PMC8287458</ArticleId><ArticleId IdType="pubmed">34326911</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer ME, Taub IB, Kaelber DC (2021) Risk of myocarditis from COVID&#x2011;19 infection in people under age 20: a population-based analysis. https://www.medrxiv.org/content/10.1101/2021.07.23.21260998v1. Zugegriffen: 1. Sept. 2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.23.21260998v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilich T, Nelde A, Heitmann JS, Maringer Y, Roerden M, Bauer J, et al. T cell and antibody kinetics delineate SARS-CoV&#x2011;2 peptides mediating long-term immune responses in COVID&#x2011;19 convalescent individuals. Sci Transl Med. 2021;13:590. doi: 10.1126/scitranslmed.abf7517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abf7517</ArticleId><ArticleId IdType="pmc">PMC8128286</ArticleId><ArticleId IdType="pubmed">33723016</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung JH, Rha M-S, Sa M, Choi HK, Jeon JH, Seok H, et al. SARS-CoV&#x2011;2-specific T cell memory is sustained in COVID&#x2011;19 convalescent patients for 10&#xa0;months with successful development of stem cell-like memory T cells. Nat Commun. 2021;12(1):4043. doi: 10.1038/s41467-021-24377-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24377-1</ArticleId><ArticleId IdType="pmc">PMC8245549</ArticleId><ArticleId IdType="pubmed">34193870</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao L, Wang G-L, Shen Y, Wang Z-Y, Zhan B-D, Duan L-J, et al. Persistence of antibody and cellular immune responses in COVID&#x2011;19&#xa0;patients over nine months after infection. J Infect Dis. 2021 doi: 10.1093/infdis/jiab255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab255</ArticleId><ArticleId IdType="pmc">PMC8243600</ArticleId><ArticleId IdType="pubmed">33978754</ArticleId></ArticleIdList></Reference><Reference><Citation>Renk H, Dulovic A, Becker M, Fabricius D, Zernickel M, Junker D et al (2021) Typically asymptomatic but with robust antibody formation: children&#x2019;s unique humoral immune response to SARS-coV&#x2011;2. https://www.medrxiv.org/content/10.1101/2021.07.20.21260863v1. Zugegriffen: 1. Sept. 2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.20.21260863v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Viner RM, Mytton OT, Bonell C, Melendez-Torres G, Ward J, Hudson L, et al. Susceptibility to SARS-CoV&#x2011;2 infection among children and adolescents compared with adults: a&#xa0;systematic review and meta-analysis. JAMA Pediatr. 2021;175(2):143&#x2013;156. doi: 10.1001/jamapediatrics.2020.4573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2020.4573</ArticleId><ArticleId IdType="pmc">PMC7519436</ArticleId><ArticleId IdType="pubmed">32975552</ArticleId></ArticleIdList></Reference><Reference><Citation>Galow L, Haag L, Kahre E, Blankenburg J, Dalpke AH, Luck C, et al. Lower household transmission rates of SARS-CoV&#x2011;2 from children compared to adults. J Infect. 2021;83(1):e34&#x2013;e6. doi: 10.1016/j.jinf.2021.04.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.04.022</ArticleId><ArticleId IdType="pmc">PMC8079264</ArticleId><ArticleId IdType="pubmed">33930468</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoeps A, Hoffmann D, Tamm C, Vollmer B, Haag S, Kaffenberger T et al (2021) COVID&#x2011;19 transmission in educational institutions august to december 2020 in Germany: a&#xa0;study of index cases and close contact cohorts. https://www.medrxiv.org/content/10.1101/2021.02.04.21250670v2.full. Zugegriffen: 1. Sept. 2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.02.04.21250670v2.full</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tzinger F, Santiago-Garc&#xed;a B, Noguera-Juli&#xe1;n A, Lanaspa M, Lancella L, Carducci FIC, et al. COVID&#x2011;19 in children and adolescents in Europe: a&#xa0;multinational, multicentre cohort study. Lancet Child Adolesc. Health. 2020;4(9):653&#x2013;661. doi: 10.1016/S2352-4642(20)30177-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(20)30177-2</ArticleId><ArticleId IdType="pmc">PMC7316447</ArticleId><ArticleId IdType="pubmed">32593339</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff K, Smith C, Silveira L, Jung S, Curran-Hays S, Jarjour J, et al. Risk factors for severe COVID&#x2011;19 in children. Pediatr Infect Dis J. 2021;40(4):e137&#x2013;e45. doi: 10.1097/INF.0000000000003043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003043</ArticleId><ArticleId IdType="pubmed">33538539</ArticleId></ArticleIdList></Reference><Reference><Citation>Clift AK, Coupland CAC, Keogh RH, Hemingway H, Hippisley-Cox J. COVID&#x2011;19 mortality risk in down syndrome: results from a&#xa0;cohort study of 8 million adults. Ann Intern Med. 2021;174(4):572&#x2013;576. doi: 10.7326/M20-4986.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-4986</ArticleId><ArticleId IdType="pmc">PMC7592804</ArticleId><ArticleId IdType="pubmed">33085509</ArticleId></ArticleIdList></Reference><Reference><Citation>Malle L, Gao C, Hur C, Truong HQ, Bouvier NM, Percha B, et al. Individuals with down syndrome hospitalized with COVID&#x2011;19 have more severe disease. Genet Med. 2021;23(3):576&#x2013;580. doi: 10.1038/s41436-020-01004-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41436-020-01004-w</ArticleId><ArticleId IdType="pmc">PMC7936948</ArticleId><ArticleId IdType="pubmed">33060835</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhopal SS, Bagaria J, Olabi B, Bhopal R. Children and young people remain at low risk of COVID&#x2011;19 mortality. Lancet Child Adolesc Health. 2021;5(5):e12&#x2013;e3. doi: 10.1016/S2352-4642(21)00066-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(21)00066-3</ArticleId><ArticleId IdType="pmc">PMC7946566</ArticleId><ArticleId IdType="pubmed">33713603</ArticleId></ArticleIdList></Reference><Reference><Citation>Armann J, Doenhardt M, Hufnagel M, Diffloth N, Reichert F, Haas W et al (2021) Risk factors for hospitalization, disease severity and mortality in children and adolescents with COVID&#x2011;19: results from a&#xa0;nationwide German registry. https://www.medrxiv.org/content/10.1101/2021.06.07.21258488v1. Zugegriffen: 1. Sept. 2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.07.21258488v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed H, Patel K, Greenwood D, Halpin S, Lewthwaite P, Salawu A et al (2021) Long-term clinical outcomes in survivors of coronavirus outbreaks after hospitalisation or ICU admission: a systematic review and meta-analysis of follow-up studies. https://www.medrxiv.org/content/10.1101/2020.04.16.20067975v1. Zugegriffen: 1. Sept. 2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.16.20067975v1</ArticleId><ArticleId IdType="pubmed">32449782</ArticleId></ArticleIdList></Reference><Reference><Citation>Deutsche Gesellschaft f&#xfc;r p&#xe4;diatrische Infektiologie (DGPI) (2021) Aktuelle Ergebnisse der Datensammlung von Pediatric Inflammatory Multisystem Syndrome (PIMS) F&#xe4;llen bei Kindern und Jugendlichen in Deutschland. https://dgpi.de/pims-survey-update/. Zugegriffen: 28. Aug. 2021</Citation></Reference><Reference><Citation>McArdle AJ, Vito O, Patel H, Seaby EG, Shah P, Wilson C, et al. Treatment of multisystem inflammatory syndrome in children. N Engl J Med. 2021;385(1):11&#x2013;22. doi: 10.1056/NEJMoa2102968.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2102968</ArticleId><ArticleId IdType="pmc">PMC8220965</ArticleId><ArticleId IdType="pubmed">34133854</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed M, Advani S, Moreira A, Zoretic S, Martinez J, Chorath K, et al. Multisystem inflammatory syndrome in children: a systematic review. EClinicalMedicine. 2020;26:100527. doi: 10.1016/j.eclinm.2020.100527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100527</ArticleId><ArticleId IdType="pmc">PMC7473262</ArticleId><ArticleId IdType="pubmed">32923992</ArticleId></ArticleIdList></Reference><Reference><Citation>Salzman MB, Huang C-W, O&#x2019;Brien CM, Castillo RD. Multisystem inflammatory syndrome after SARS-coV-2 infection and COVID&#x2011;19 vaccination. Emerg Infect Dis. 2021;27(7):1944. doi: 10.3201/eid2707.210594.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2707.210594</ArticleId><ArticleId IdType="pmc">PMC8237872</ArticleId><ArticleId IdType="pubmed">34034858</ArticleId></ArticleIdList></Reference><Reference><Citation>Uwaydah AK, Hassan NM, Ghoush MSA, Shahin KMM. Adult multisystem inflammatory syndrome in a&#xa0;patient who recovered from COVID&#x2011;19 postvaccination. BMJ Case Rep. 2021;14(4):e242060. doi: 10.1136/bcr-2021-242060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2021-242060</ArticleId><ArticleId IdType="pmc">PMC8061568</ArticleId><ArticleId IdType="pubmed">33883119</ArticleId></ArticleIdList></Reference><Reference><Citation>Nittas V, Puhan M. Literature screening report: long COVID: evolving definitions, burden of disease and socio-economic consequences. 2021.</Citation></Reference><Reference><Citation>Brackel CLH, Lap CR, Buddingh EP, van Houten MA, van der Sande L, Langereis EJ, et al. Pediatric long-COVID: an overlooked phenomenon? Pediatr Pulmonol. 2021 doi: 10.1002/ppul.25521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ppul.25521</ArticleId><ArticleId IdType="pmc">PMC8242715</ArticleId><ArticleId IdType="pubmed">34102037</ArticleId></ArticleIdList></Reference><Reference><Citation>Blankenburg J, Wekenborg MK, Reichert J, Kirsten C, Kahre E, Haag L et al (2021) Mental health of adolescents in the pandemic: long-COVID19 or long-pandemic syndrome? https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3844826. Zugegriffen: 1. Sept. 2021</Citation></Reference><Reference><Citation>Radtke T, Ulyte A, Puhan MA, Kriemler S (2021) Long-term symptoms after SARS-CoV&#x2011;2 infection in school children: population-based cohort with 6&#x2011;months follow-up. https://www.medrxiv.org/content/10.1101/2021.05.16.21257255v2. Zugegriffen: 1. Sept. 2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.16.21257255v2</ArticleId></ArticleIdList></Reference><Reference><Citation>RKI (2021) RKI Lagebericht &#xfc;ber das aktuelle Infektionsgeschehen in Deutschland. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Gesamt.html. Zugegriffen: 08.10.2021</Citation></Reference><Reference><Citation>RKI (2021) W&#xf6;chentlicher Lagebericht des RKI zur Coronavirus-Krankheit-2019 vom 19.08.2021. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Wochenbericht/Wochenbericht_2021-08-19.pdf?__blob=publicationFile. Zugegriffen: 08.10.2021</Citation></Reference><Reference><Citation>Deutsche Gesellschaft f&#xfc;r p&#xe4;diatrische Infektiologie (DGPI) (2021) Aktuelle Ergebnisse der DGPI-Datensammlung von station&#xe4;ren COVID&#x2011;19&#xa0;F&#xe4;llen bei Kindern und Jugendlichen in Deutschland. https://dgpi.de/covid-19-survey-update/. Zugegriffen: 1. Sept. 2021</Citation></Reference><Reference><Citation>Twohig KA, Nyberg T, Zaidi A, Thelwall S, et al. Hospital admission and emergency care attendance risk for SARS-CoV&#x2011;2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet. 2021 doi: 10.1016/S1473-3099(21)00475-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00475-8</ArticleId><ArticleId IdType="pmc">PMC8397301</ArticleId><ArticleId IdType="pubmed">34461056</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenck RW, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid&#x2011;19 vaccine in adolescents. N Engl J Med. 2021;385(3):239&#x2013;250. doi: 10.1056/NEJMoa2107456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107456</ArticleId><ArticleId IdType="pmc">PMC8174030</ArticleId><ArticleId IdType="pubmed">34043894</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M, et al. Evaluation of mRNA-1273 SARS-CoV&#x2011;2 vaccine in adolescents. N Engl J Med. 2021 doi: 10.1056/NEJMoa2109522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2109522</ArticleId><ArticleId IdType="pmc">PMC8385554</ArticleId><ArticleId IdType="pubmed">34379915</ArticleId></ArticleIdList></Reference><Reference><Citation>Norwegian Medicines Agency (2021) Reports of suspected adverse reactions to COVID&#x2011;19 vaccines as of 27 april 2021. https://legemiddelverket.no/nyheter/reports-of-suspected-adverse-reactions-to-covid-19-vaccines-as-of-27-april-2021. Zugegriffen: 28. Mai 2021</Citation></Reference><Reference><Citation>Larson KF, Ammirati E, Adler ED, Cooper LT, Hong KN, Saponara G, et al. Myocarditis after BNT162b2 and mRNA-1273 vaccination. Circulation. 2021;144(6):506&#x2013;508. doi: 10.1161/CIRCULATIONAHA.121.055913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.055913</ArticleId><ArticleId IdType="pmc">PMC8340725</ArticleId><ArticleId IdType="pubmed">34133884</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouch SA, Roguin A, Hellou E, Ishai A, Shoshan U, Mahamid L, et al. Myocarditis following COVID&#x2011;19 mRNA vaccination. Vaccine. 2021;39(29):3790&#x2013;3793. doi: 10.1016/j.vaccine.2021.05.087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.05.087</ArticleId><ArticleId IdType="pmc">PMC8162819</ArticleId><ArticleId IdType="pubmed">34092429</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosner CM, Genovese L, Tehrani BN, Atkins M, Bakhshi H, Chaudhri S, et al. Myocarditis temporally associated with COVID&#x2011;19 vaccination. Circulation. 2021;144(6):502&#x2013;505. doi: 10.1161/CIRCULATIONAHA.121.055891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.055891</ArticleId><ArticleId IdType="pmc">PMC8340723</ArticleId><ArticleId IdType="pubmed">34133885</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency (EMA) (2021) Comirnaty and Spikevax: possible link to very rare cases of myocarditis and pericarditis. https://www.ema.europa.eu/en/news/comirnaty-spikevax-possible-link-very-rare-cases-myocarditis-pericarditis. Zugegriffen: 22. Juli 2021</Citation></Reference><Reference><Citation>Shimabukuro T (2021) Advisory committee on immunization practices (ACIP). COVID&#x2011;19 vaccine safety updates. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-06/03-COVID-Shimabukuro-508.pdf. Zugegriffen: 08.10.2021</Citation></Reference><Reference><Citation>Hause AM, Gee J, Baggs J, et al. COVID&#x2011;19 vaccine safety in adolescents aged 12&#x2013;17 years&#x2014;United States, december 14, 2020&#x2013;july 16, 2021. Mmwr Morb Mortal Wkly Rep. 2021;70:1053&#x2013;1058. doi: 10.15585/mmwr.mm7031e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7031e1</ArticleId><ArticleId IdType="pmc">PMC8367318</ArticleId><ArticleId IdType="pubmed">34351881</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (2021) Estimated COVID&#x2011;19 infections, symptomatic illnesses, and hospitalizations&#x2014;United States. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/burden.html. Zugegriffen: 1. Sept. 2021</Citation></Reference><Reference><Citation>Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID&#x2011;19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices&#x2014;United States, June 2021. Mmwr Morb Mortal Wkly Rep. 2021;70:977&#x2013;982. doi: 10.15585/mmwr.mm7027e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7027e2</ArticleId><ArticleId IdType="pmc">PMC8312754</ArticleId><ArticleId IdType="pubmed">34237049</ArticleId></ArticleIdList></Reference><Reference><Citation>PEI (2021) Sicherheitsbericht. Verdachtsf&#xe4;lle von Nebenwirkungen und Impfkomplikationen nach Impfung zum Schutz vor COVID&#x2011;19 seit Beginn der Impfkampagne am 27.12.2020 bis zum 31.07.2021. https://www.pei.de/SharedDocs/Downloads/DE/newsroom/dossiers/sicherheitsberichte/sicherheitsbericht-27-12-bis-31-07-21.pdf?__blob=publicationFile&amp;v=5. Zugegriffen: 08.10.2021</Citation></Reference><Reference><Citation>Jain SS, Steele JM, Fonseca B, Huang S, Shah S, Maskatia SA, et al. COVID&#x2011;19 vaccination-associated myocarditis in adolescents. Pediatrics. 2021 doi: 10.1542/peds.2021-053427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2021-053427</ArticleId><ArticleId IdType="pubmed">34389692</ArticleId></ArticleIdList></Reference><Reference><Citation>Vygen-Bonnet SKJ, Berner R, Bogdan C, Harder T, Heininger U, Hummers E, Littmann M, Meerpohl J, Mertens T, Meyer H, Neufeind J, Schmid-K&#xfc;pke N, Scholz S, Terhardt M, &#xdc;berla K, van der Sande M, Waize M, Wichmann O, Wicker S, Widders G, Wiedermann U, Wild V, Zepp F, von Kries R. Beschluss der STIKO zur 6. Aktualisierung der COVID&#x2011;19-Impfempfehlung und die dazugeh&#xf6;rige wissenschaftliche Begr&#xfc;ndung. Epidemiol Bull. 2021;23:3&#x2013;32.</Citation></Reference><Reference><Citation>Oliver S et al (2021) EtR framework: Pfizer-bioNtech COVID&#x2011;19 vaccine in adolescents aged 12-15 years. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-05-12/04-COVID-Oliver-508.pdf. Zugegriffen: 08.10.2021</Citation></Reference><Reference><Citation>CDC (2021) Provisional COVID&#x2011;19 death counts by age in years. https://data.cdc.gov/NCHS/Provisional-COVID-19-Deaths-Counts-by-Age-in-Years/3apk-4u4f/data. Zugegriffen: 08.10.2021</Citation></Reference><Reference><Citation>RKI (2021) Anhang 1 zur wissenschaftlichen Begr&#xfc;ndung der STIKO-Empfehlung zur COVID&#x2011;19-Impfung. Mathematische Modellierung. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/33_21_Anhang_1.pdf?__blob=publicationFile. Zugegriffen: 08.10.2021</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>